Granite Investment Partners, LLC Eagle Pharmaceuticals, Inc. Transaction History

Granite Investment Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$36.72 - $67.73 $7.63 Million - $14.1 Million	-207,799 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$66.65 - $83.86 $601,516 - $756,836	9,025 Added 4.54%	207,799 $14.4 Million
Q2 2018 Aug 06, 2018	BUY	$51.25 - $76.62 $4.33 Million - $6.48 Million	84,567 Added 74.05%	198,774 $15 Million
Q1 2018 May 04, 2018	SELL	$52.16 - $66.86 $10,953 - $14,040	-210 Reduced 0.18%	114,207 $6.02 Million
Q4 2017 Feb 01, 2018	BUY	$49.6 - $60.87 $152,420 - $187,053	3,073 Added 2.76%	114,417 $6.11 Million
Q3 2017 Nov 08, 2017	BUY	$46.62 - $60.36 $5.19 Million - $6.72 Million	111,344	111,344 $6.64 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Granite Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Granite Investment Partners, LLC with notifications on news.